NSE: ABBOTINDIA | BSE: 500488

Expensive Performer

Download real time

30365.00 -525.00 (-1.70%)

13,279 NSE+BSE Volume

NSE 19 Sep, 2025 3:31 PM (IST)

64,523.5

Market Cap

High in industry

0.5

Beta 1Year

Very Low volatility

Analyst Buy

Sharekhan retains its 'Buy' call on Abbott India, expects a revenue CAGR of 9.4% over FY26-27 See details

Abbott India Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ABBOTINDIA, BSE:500488 Abbott India Ltd.

Search Inside the pdf :

Abbott India Ltd.

17 Sep 2025

30365.00

-1.70%

Steady business, outpacing Pharma peers

Buy: Abbott India Ltd.

Target

Sharekhan

Strong history of product launches: Abbott India has been steadily growing led by consistent launches of both - own and Novo Nordisk’s products (marketing). Abbott India has launched over 100 products in India in the last 12 years and we expect the pipeline to stay strong.

Abbott India Ltd. is trading below all available SMAs

Abbott India Ltd.

04 Jul 2025

30365.00

-1.70%

Abbott India (BUY): Ascribing valuation in line with its peer GSK

Buy: Abbott India Ltd.

Target

BOB Capital Markets Ltd.

Novo's oral semaglutide Rybelsus is growing at a robust 173% CAGR over a 3Y period to Rs 4bn, as on MAT MAY'25

Abbott India Ltd. has an average target of 35337.00 from 4 brokers.

Abbott India Ltd.

16 May 2025

30365.00

-1.70%

Sustained improvement across the board

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott India’s (Abbott) revenue grew 12% YoY ahead of most MNCs (avg. growth of ~10% YoY and IPM growth of ~8% YoY in Q4FY25). Abbott’s growth was aided by healthy traction in its own brands along with key brands of Novo Nordisk like Rybelsus and Ryzodeg.

Abbott India Ltd. has an average target of 35337.00 from 4 brokers.

Abbott India Ltd.

29 Apr 2025

30365.00

-1.70%

ERRATA: Abbott India (BUY): Mixtard discard to result in highest-ever EBITDA margin

Buy: Abbott India Ltd.

BOB Capital Markets Ltd.

Novo Nordisk insulin brand outgo to result in 330 bps and 670 bps increase in EBITDA margin to 30.9% and 34.9% for FY26E and FY27E

Abbott India Ltd. is trading below all available SMAs

Abbott India Ltd.

11 Apr 2025

30365.00

-1.70%

[Initiation] Abbott India (BUY): A safe pick amidst tariff woes

Buy: Abbott India Ltd.

BOB Capital Markets Ltd.

Sales expected to reach USD 1bn, driven by industry-leading MR productivity of Rs 14.9mn by FY27E from Rs 11.5mn in FY24

Abbott India Ltd. has an average target of 35337.00 from 4 brokers.

Abbott India Ltd.

06 Feb 2025

30365.00

-1.70%

Stellar quarter; growth pace accelerating

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott India’s (Abbott) impressive revenue growth of 12.3% YoY in Q3FY25 was ahead of our expectation. As per IQVIA, this may be driven by key brands of Novo Nordisk like Rybelsus and Ryzodeg and owned brands like Duphalac, Udiliv and Thyronorm.